New research suggests that individuals who come off new GLP-1 drugs like Wegovy and Mounjaro may regain shed pounds much more quickly than those who stop conventional diet and exercise regimens.
Findings released in a leading health publication shows that while overweight individuals frequently drop a large proportion of their body weight while using the jabs, the weight is regained at an estimated rate of nearly a kilo each month once they quit.
"People buying such medications should be cognizant of the potential of rapid weight regain when the therapy concludes," stated lead investigator Dr. Susan Jebb.
This pace of recovery implies a return to pre-treatment mass in about a year and a half.
Analyzing Approaches
The research, which reviewed 37 of studies involving over 9,000 of participants, contrasted the outcomes of these new drugs with conventional dieting.
Researchers note that individuals who lose weight through lifestyle changes alone usually see a less rapid creep back—around 0.1 kg a month—post-intervention.
The Reason for the Quick Rebound
Experts believe the mechanism of the jabs is key to understanding the heightened weight return.
The injections copy a body's own chemical called GLP-1, which helps regulate appetite.
"Long-term administration of the hormone levels several times higher than the body's typical production could lead to the system to produce less of its endogenous hormone, and could diminish sensitivity to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this medication results in hunger is unsuppressed, making overeating far more likely."
A Chronic Disease?
The NHS recommend the injections for people with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
Many experts contend that, considering the significant potential of weight regain, the therapy is often long-term.
This opinion is reinforced by drug manufacturers, who note that the findings "highlight the chronic character of obesity," comparing it to managing diseases like high blood pressure.
Patient Experiences
Individuals who have discontinued the jabs explain a intense resurgence of hunger.
"I experienced something activating and you're instantly extremely hungry," said one woman.
This difficulty is compounded if patients have not adopted lasting dietary or behavioural modifications during treatment.
Widespread Adoption
Recent estimates suggest that millions of adults in the UK have tried weight-loss jabs in the past year, with desire continuing to grow.
- Use is higher among females compared to men.
- The 40s and 50s demographic shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than public health services.
Ultimately, researchers stress that while GLP-1 drugs are potent tools for weight loss, they are not a permanent cure and lasting health benefits hinges on ongoing lifestyle support.